Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 28 Issue 11, November 2010

Therapeutic IgG antibodies bind only two antigen molecules during their lifetime. Igawa et al. engineer antibody recycling through pH-dependent binding, which allows the antigen to be released in the endosome for lysosomal degradation while the antibody is returned to the plasma for additional rounds of antigen binding (p 1203). Credit: JOLLYBOY and Sakura Motion Picture Co., Ltd.

Editorial

  • Claims of conflicts of interest concerning authorship of a scientific paper highlight the difficulties facing regulators participating in collaborations with industry.

    Editorial

    Advertisement

Top of page ⤴

News

Top of page ⤴

Data Page

Top of page ⤴

News Feature

  • Impatient with the slow pace of clinical research, families of individuals suffering from untreatable diseases are taking matters into their own hands—with some success. Virginia Hughes reports.

    • Virginia Hughes
    News Feature
Top of page ⤴

Correspondence

Top of page ⤴

Commentary

  • Efficiently generating evidence of clinical utility is a major challenge for ensuring clinical adoption of valuable diagnostics. A new approach to reimbursement in the United States offers a balance between evidence and incentives for molecular diagnostic tests.

    • Kevin A Schulman
    • Sean R Tunis
    Commentary
  • Coverage with evidence development (CED), rather than quality-adjusted-life-year (QALY) thresholds, offers the best way forward in balancing evidence-based policy for new oncology products with the needs of developers, payers, physicians and patients.

    • Joshua Cohen
    • William Looney
    Commentary
Top of page ⤴

Feature

  • Last year, the biologics sector managed single-digit growth in the United States, driven mainly by products indicated for oncology, diabetes and autoimmune disorders. Lurking on the horizon, though, are challenges, such as pricing, competition and follow-on molecules.

    • Saurabh Aggarwal
    Feature
Top of page ⤴

Patents

Top of page ⤴

News & Views

Top of page ⤴

Research Highlights

Top of page ⤴

Commentary

Top of page ⤴

Article

  • Degeneration of articular cartilage in the joints may be amenable to tissue engineering solutions. Oldershaw et al. present an efficient, chemically defined protocol for differentiating human ES cells to chondrocyte-like cells.

    • Rachel A Oldershaw
    • Melissa A Baxter
    • Susan J Kimber
    Article
  • Antibodies that modulate the activity of a target are difficult to discover with display-based approaches, which select only high-affinity binders. Mao et al. identify antibodies with a range of affinities using a small-molecule discovery method that involves one-by-one screening of an optimized small library of antibody fragments with known sequences.

    • Hongyuan Mao
    • James J Graziano
    • Vaughn V Smider
    Article
Top of page ⤴

Letter

  • The simultaneous detection of multiple mRNA species in thick tissues or whole-mount embryos has remained technically challenging. Choi et al. present a method based on the triggered polymerization of RNA stem-loop structures that allows the distribution of up to five mRNAs in intact zebrafish embryos to be imaged at the same time.

    • Harry M T Choi
    • Joann Y Chang
    • Niles A Pierce
    Letter
  • The culture of dedifferentiated plant cells to produce commercially important chemicals has met with limited success. Lee et al. demonstrate the potential of innately undifferentiated cells from Taxus cuspidata as an industrial source of the anticancer drug paclitaxel.

    • Eun-Kyong Lee
    • Young-Woo Jin
    • Gary J Loake
    Letter
Top of page ⤴

Careers and Recruitment

Top of page ⤴

Search

Quick links